^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

HM16390

i
Other names: HM16390, HM 16390, HM-16390
Associations
Trials
Company:
Hanmi
Drug class:
IL-2 stimulant
Related drugs:
Associations
Trials
over1year
A long-acting and CD122-enhanced IL-2 analog, HM16390, synergizes with immune checkpoint inhibitor by remodeling an immune cell profile in tumor microenvironment (AACR 2023)
B16F10 mice were sacrificed at days 1, 3, and 8 following single subcutaneous administration of HM16390 or 5 consecutive daily administrations of aldesleukin. In conclusion, HM16390 effectively induced tumor growth inhibition through the activation and tumor infiltration of cytotoxic lymphocytes. This favorable immune alteration in tumor elicited a TME remodeling in which CPI could sufficiently respond.
Checkpoint inhibition • Immune cell
|
CD8 (cluster of differentiation 8) • IFNG (Interferon, gamma) • TNFA (Tumor Necrosis Factor-Alpha) • IL2 (Interleukin 2)
|
Proleukin (aldesleukin) • HM16390
over1year
A long-acting and CD122-enhanced IL-2 analog, HM16390, shows a potent and durable anti-tumor effect in both syngeneic B16F10 or CT26 mouse models (AACR 2023)
Although recombinant IL-2 (aldesleukin) was approved for the treatment of metastatic renal cell carcinoma and melanoma, its suboptimal ligand binding affinity required high-dose administrations, resulting in dose-limiting toxicity such as vascular leak syndrome. Of note, at doses ≥17 mg/kg, CR was observed in up to 22% of the mice. To sum up with the results, HM16390 has a dose-dependent and potent anti-tumor efficacy in murine models with the broad range of the immunogenic condition via CD122-enhanced IL-2 agonism.
Preclinical
|
IL2RA (Interleukin 2 receptor, alpha) • IL2 (Interleukin 2) • ISG20 (Interferon Stimulated Exonuclease Gene 20)
|
Proleukin (aldesleukin) • HM16390